-
Featured
Brain Infusion of Genetically Modified Poliovirus Is Used to Treat Glioblastoma
A phase II trial kicked off at Massachusetts General Hospital involving multiple departments and research institutes are utilizing oncolytic viruses to treat glioblastomas.
-
Featured
Combined Blockade of ATR and PARP Effective Against Glioblastoma in Mice
The combination of olaparib and an ATR inhibitor was effective against glioblastoma in mice, providing a much-needed therapeutic breakthrough for this deadly disease.
-
Featured
Adding an NAMPT Inhibitor to Temozolomide Might Boost Its Effect in IDH-Mutant Glioma
IDH1/2-mutant glioma is often treated with temozolomide, but most of these cancers recur. Research at Massachusetts General Hospital suggests that combining the drug with an NAMPT inhibitor may improve its anticancer effect.
-
Perspective: Using Information on Somatic Mutations to Direct Management of Neurological Disorders
Kristopher T. Kahle, MD, PhD, and colleagues explain that somatic variations detected from neurosurgical biopsies or resection of fresh brain tissue are beginning to suggest which existing targeted medications could be used as monotherapies or adjuncts to surgery for non-oncologic neurological diseases.
-
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Rishab Ramapriyan, William T. Curry, MD, Bryan D. Choi, MD, PhD, and colleagues describe the antibody-based therapies being used to treat glioblastoma and other central nervous system tumors, with special attention to the challenges of blood–brain barrier penetration and tumor-derived immunosuppression.
-
Rare IDH2-mutant Glioma Shares Common Molecular Targets With IDH1-mutant Glioma
Massachusetts General Hospital researchers provide evidence that gene alterations that activate the retinoblastoma and PDGFR pathways have a pivotal biological role in the progression of IDH2-mutant astrocytoma, which is equivalent to progressive IDH1-mutated glioma, and they identified potential drug targets.
Mass General Cancer Center Contributors
-
Bakhos A. Tannous, PhD
Associate Neuroscientist, Massachusetts General Hospital, Director, Vector Production and Development Core, Associate Professor, Harvard Medical School
Recent Article
Noninvasive Techniques in Brain Tumor Treatment -
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
Co-transplantation of Regulatory T Cells Improves Cell Replacement Therapy for Parkinson's Disease
-
Daniel P. Cahill, MD, PhD
Neurosurgeon, Massachusetts General Hospital, Neurosurgical Oncologist, Mass General Cancer Center
Recent Article
Rare IDH2-mutant Glioma Shares Common Molecular Targets With IDH1-mutant Glioma
-
Shannon Stott, PhD
Assistant Professor of Medicine, Department of Medicine, Harvard Medical School, Assistant in Genetics, Massachusetts General Hospital
Recent Article
How Liquid Biopsies Can Improve Brain Tumor Diagnoses
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Stephen E. and Catherine Pappas Center for Neuro-Oncology at Mass General
The Stephen E. and Catherine Pappas Center for Neuro-Oncology offers the most advanced care for patients with brain tumors and nervous system tumors.
